Becton, Dickinson and Co (BDX) Quote - XNYS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

COVID-Related Revenue Continues to Boost Becton, Dickinson Growth in the Third Quarter

Regional Director Alex Morozov

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA | Aug 5, 2021

We anticipate a moderate increase to our fair value estimate for narrow-moat Becton, Dickinson following the release of third quarter results and updated guidance for fiscal 2021. The third quarter of 2020 provided easy comparables for BD, having declined over 11% between 2019 and 2020, but the nearly 27% growth year over year for the quarter from 2020 to 2021 returned total revenue to levels in line with historical growth at $4.9 billion. We currently view BD as undervalued.

Read Full Analysis

Company Profile

Business Description

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Contact

1 Becton Drive
Franklin Lakes, NJ, 07417-1880

T +1 201 847-6800

kristen.stewart@bd.com

Sector Healthcare

Industry Medical Instruments & Supplies

Most Recent Earnings Jun 30, 2021

Fiscal Year End Sep 30, 2021

Stock Type Slow Growth

Employees 72,000

Related

The Winners of the New Definition of Infrastructure

Depending on which broader infrastructure projects take shape, numerous companies could see increased demand.

Stock Strategist Industry Reports

A Coronavirus Vaccine, or Three, Could Be Available by Year-End

We expect multiple approved vaccines by early 2021 with wide vaccine distribution in developed markets by mid-2021.

Stock Strategist Industry Reports

Slow Burn Likely Until Coronavirus Vaccines Are Widely Available

Resurgences in outbreaks make it clear that ending the pandemic will require more than diagnostic testing, contact tracing, and social distancing.

Premium Article

22 Meaningful Fair Value Hikes

These stocks enjoyed fair value increases in February. But are they worth buying today?

Susan Dziubinski

4 Dividend Stocks to Own

These stocks are among the top-10 holdings in several of our favorite dividend-growth funds.

Susan Dziubinski

A Fast-Growing Slice of the Healthcare Sector for Your Radar

Life science and diagnostics firms offer attractive growth and moats, but be wary of valuations.

Michael Waterhouse

A Thoughtful, Well-Researched Approach to Healthcare Investing

Silver-rated Fidelity Select Health Care's experienced manager takes a three-pronged approach to the sector.

M&A Activity Likely to Pick Up for Medical-Technology Firms

Becton Dickinson, Cardinal Health, and Abbott are all on track to make acquisitions.

Julie Utterback

Despite Manager Departure, This Fund Remains Appealing

Silver-rated Jensen Quality Growth is losing one of its skippers, but the fund has maintained its disciplined approach--and outperformance--through other departures.

5 Investing Ideas From Top Dividend-Stock Fund Managers

Three fund managers share some dividend picks.

Stock Analyst Update

Upgrading Our Growth Forecast for Becton, Dickinson

Across the firm, we are seeing the effects of significant R&D investments, with BD's pipeline the strongest it's been in our history of covering this narrow-moat medical technology company.

Large-Growth Medalists at the Extremes of Sustainability

Quite a few good large-growth funds earn high Sustainability Ratings despite not being explicitly ESG-oriented.

Stock Strategist

Baxter's Headwinds Mostly Temporary

The company faces near-term challenges after the split, but we still like its moat.

Michael Waterhouse

Investing Specialists

Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

Our Ultimate Stock-Pickers Index continues to beat the market even as relatively few of our top managers are outperforming the S&P 500.

The Morningstar Ultimate Stock-Pickers Team

Nominees for 2014 Domestic-Stock Fund Manager of the Year

Five candidates who did more than ride the market's currents.

Credit Insights

Robust Liquidity Returns to Corporate Bond Market

New issue market reaches new volume records

Credit Insights

Unusual Activity in 10-Year Treasury Hits Markets

Only best-known issuers with strong balance sheets dared tap the new issue market.

Credit Insights

Heightened Volatility Results in Sloppy Corporate Bond Trading

While marriages are increasing in the health-care sector, conscious uncoupling increases in the technology sector.

2 Names to Gain From Industry Trends

A retailer's attractive pricing and a health-care firm's favorable prospects create solid growth opportunities for Jensen manager Eric Schoenstein.

Stock Strategist Industry Reports

Patient Trends Improving, but Reimbursement Outlook Remains Bleak for Health Service Providers

Greater accountability creates a new level of operating uncertainty.

Michael Waterhouse

Transparency is our policy. Learn how it impacts everything we do.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.